about
Telomerase contributes to fludarabine resistance in primary human leukemic lymphocytes.Triterpenoids display single agent anti-tumor activity in a transgenic mouse model of chronic lymphocytic leukemia and small B cell lymphoma.Ofatumumab, a human anti-CD20 monoclonal antibody.Salvage transplantation for allograft failure using fludarabine and alemtuzumab as conditioning regimen.Enhancement of fludarabine sensitivity by all-trans-retinoic acid in chronic lymphocytic leukemia cells.STAT1 signaling modulates HIV-1-induced inflammatory responses and leukocyte transmigration across the blood-brain barrier.Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism.Spotlight on ibrutinib and its potential in frontline treatment of chronic lymphocytic leukemia.Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signalingFludarabine induces differential expression of proteins in human leukemia and lymphoma cells.All-trans-retinoic acid promotes trafficking of human concentrative nucleoside transporter-3 (hCNT3) to the plasma membrane by a TGF-beta1-mediated mechanism.Mantle cell lymphoma salvage regimen: synergy between a reprogrammed oncolytic virus and two chemotherapeutics.Ibrutinib downregulates a subset of miRNA leading to upregulation of tumor suppressors and inhibition of cell proliferation in chronic lymphocytic leukemia.Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells.Unusual Relapse of Chronic Lymphocytic Leukemia After Remission.Treatment Sequencing in a Chronic Lymphocytic Leukemia Patient with Central Nervous System Involvement.
P2860
Q31125909-04A79DD2-1F85-4544-865F-4CAAE1D6D090Q33288957-2DBCEEC3-C7D6-4D10-A5CD-AF5AA9226C5AQ34095311-DCE23994-8B5E-4BAC-B300-AD6D412E0A2DQ34180301-4C7F0227-6258-4E69-AB01-525A88D6911BQ36006445-A0491D0A-432C-4C5E-A2F1-3A010FC340D3Q36445840-B7D992F6-6766-443B-A918-641EE7943305Q36843744-10EA9ECF-DE99-43D6-A95D-A846AC830F7CQ37742056-36EA122F-1A51-4BF0-BC71-96208C3E09BBQ38069567-4E62B718-DDF9-4090-9FE8-7C5011EE156AQ39965272-6F1CE2D9-9C2A-447D-9415-27CBD4803C5CQ40187312-BD8EEDAB-A771-4F34-9716-DFD4D39BC9EEQ42080758-E676D7CA-CEC2-4CC0-BFBC-E068E882F4C8Q46689848-F1836092-41B0-4A14-A3FB-2C4335178867Q54407620-834A830B-1BDA-4AFE-9C4E-C91C80D4CB19Q55040890-B7E2F0F9-7001-4A9A-8921-3DD7BE3A7169Q55411364-88EFC6C0-8739-45EC-AC47-88448F5EC71B
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Fludarabine in chronic lymphocytic leukaemia.
@ast
Fludarabine in chronic lymphocytic leukaemia.
@en
type
label
Fludarabine in chronic lymphocytic leukaemia.
@ast
Fludarabine in chronic lymphocytic leukaemia.
@en
prefLabel
Fludarabine in chronic lymphocytic leukaemia.
@ast
Fludarabine in chronic lymphocytic leukaemia.
@en
P2860
P1476
Fludarabine in chronic lymphocytic leukaemia.
@en
P2093
Andreas Engert
Thomas Elter
P2860
P304
P356
10.1517/14656566.7.12.1641
P407
P577
2006-08-01T00:00:00Z